The cost of adjuvant chemotherapy in patients with early‐stage breast carcinoma

Abstract

BACKGROUNDIn the U.S., the majority of premenopausal patients with early‐stage breast carcinoma are treated with adjuvant chemotherapy. However, to the authors' knowledge, there have been few formal analyses of adjuvant chemotherapy cost performed to date, especially in premenopausal women. The objective of the current study was to evaluate the direct medical cost of adjuvant chemotherapy in women with early‐stage breast carcinoma.METHODSThe attributable cost of adjuvant chemotherapy was evaluated by comparing the total cost of care for patients with breast carcinoma (cases) during the period from diagnosis to 9 months subsequent with the cost for age‐matched and gender‐matched control patients without breast carcinoma over an equivalent time period. The authors identified cases from a linked database of claims records from a managed care organization, and the Cancer Surveillance System registry. Controls were identified from the managed care organization from which the cases originated. Resource prices were based on reimbursements from the managed care organization.RESULTSThe attributable cost of adjuvant chemotherapy was estimated to be $23,019 (95% confidence interval, $19,596–$26,441), based on 1239 women. The cost appeared to decrease with increasing age at diagnosis, with total costs of $26,834, $19,889, and $17,098 for women < 50, 50–59, and ≥ 60 years, respectively. Also, costs were higher for regional versus local disease ($36,076 vs. $12,659), for women who had a mastectomy versus breast‐conserving surgery ($31,075 vs. $17,889), and for women who had no comorbidities versus ≥ 1 comorbidity ($23,606 vs. $21,340). Contributors to high chemotherapy cost included use of chemotherapy agents not included in clinical guidelines during the study period, use of supportive care agents, and hospitalizations.CONCLUSIONSThe attributable cost of adjuvant chemotherapy in patients with early‐stage breast carcinoma is significant. The integration of managed care claims data with clinical data from the Cancer Surveillance System registry offered a unique opportunity to derive more informative and accurate disease burden estimates in oncology. Cancer 2005. © 2005 American Cancer Society.

The influence of a Gene expression profile on breast cancer decisions

“…We view this as particularly encouraging considering the cost of the assay. Although our study was neither intended nor designed to address cost-effectiveness, our data suggest that the $$3,500 cost of the assay for each of our 29 patients is offset by the net reduction of 5 patients receiving adjuvant chemotherapy at a cost of $ $23,000 each (in 2003 dollars) [18].…”

The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort

“…For instance, the approximate cost of four cycles of docetaxel and cyclophosphamide for those 37 women is approximately $350,000, while the cost of ODX testing is $150,000. These estimated cost savings are underestimated as additional costs of growth factor support, laboratory monitoring, or other supportive care costs associated with CTX administration have not been taken into account [17].…”

Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer

“…A key driver of clinical and economic impact for assays used in this setting is the degree to which providers and patients change their behavior based on the test results.This impact will vary over time as more evidence emerges and providers and patients gain experience with the test. Finally, as is common with assays used in early stage cancer, there can be a slight mortality increase with assay use because of decreased aggressive treatment with slight survival benefit, but that effect is eclipsed in the composite QALY measure due to the improvements in patient quality of life related to avoidance of treatment-associated complications [33][34][35].…”